Bioventus Inc Revenue Growth Rates (BVS), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Bioventus Inc   (NASDAQ: BVS)
 

BVS's Revenue Growth by Quarter and Year

Bioventus Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/BVS/growth
https://api.csimarket.com/api/v1/companies/BVS/fundamentals
https://api.csimarket.com/api/v1/companies/BVS/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
BVS Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 142.44
2nd Quarter June 153.21
1st Quarter March 131.77
FY 427.42

BVSs Annual Revenue
Bioventus Inc 's Revenue in the fiscal year 2025 $ 567.16 millions
Bioventus Inc 's Revenue in the fiscal year 2024 $ 573.23 millions
Bioventus Inc 's Revenue in the fiscal year 2023 $ 512.19 millions
Bioventus Inc 's Revenue in the fiscal year 2022 $ 512.08 millions
Bioventus Inc 's Revenue in the fiscal year 2021 $ 430.90 millions




BVS Revenue third quarter 2026 Y/Y Growth Comment
Bioventus Inc reported Revenue growth of 3.05% year on year in the third quarter 2026, to $ 142.44 millions, this is lower than Bioventus Inc 's recent average Revenue increase of 13.27%.

Looking into third quarter 2026 results within Medical Equipment & Supplies industry 119 other companies have achieved higher Revenue growth. While Bioventus Inc ' s Revenue increase of 3.05% ranks overall at the positon no. 2389 in the third quarter 2026.


BVS Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 3.05 %
2nd Quarter June 3.76 %
1st Quarter March 7.08 %
FY   -

Financial Statements
Bioventus Inc 's third quarter 2026 Revenue $ 142.44 millions BVS's Income Statement
Bioventus Inc 's third quarter 2025 Revenue $ 138.23 millions Quarterly BVS's Income Statement


BVS Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -7.03 %
2nd Quarter June 16.27 %
1st Quarter March -16.55 %
FY (Year on Year)   -


Back to BVS Growth rate Comparisons >> Back to BVS Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #120
Healthcare Sector #346
Overall #2389

Revenue Y/Y Growth Statistics
High Average Low
89.28 % 13.27 % -6.76 %
(Apr 02 2022)   (Sep 30 2023)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #120
Healthcare Sector #346
Overall #2389
Revenue Y/Y Growth Statistics
High Average Low
89.28 % 13.27 % -6.76 %
(Apr 02 2022)   (Sep 30 2023)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Bioventus Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
48.07 % 4.19 % -26.23 %
(Sep 26 2020)  


BVS's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Bioventus Inc disclosed drop in Revenue from the second quarter by -7.03% to $ 142.44 millions, from $ 153.21 millions achived in the previous reporting period.

But that's not important problem, as Bioventus Inc 's Revenue generally seem to plunge in this quarter.

Within Medical Equipment & Supplies industry 29 other companies have achieved higher Revenue quarter on quarter growth. While Bioventus Inc 's Revenue growth quarter on quarter, overall rank is 604.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #30
Healthcare Sector #111
Overall #604
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #30
Healthcare Sector #111
Overall #604
Revenue Q/Q Growth Statistics
High Average Low
48.07 % 4.19 % -26.23 %
(Sep 26 2020)  


BVS's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Bioventus Inc disclosed drop in Revenue from the second quarter by -7.03% to $ 142.44 millions, from $ 153.21 millions achived in the previous reporting period.

But that's not important problem, as Bioventus Inc 's Revenue generally seem to plunge in this quarter.

Within Medical Equipment & Supplies industry 29 other companies have achieved higher Revenue quarter on quarter growth. While Bioventus Inc 's Revenue growth quarter on quarter, overall rank is 604.


Bioventus Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 26 2026)		 12 Months Ending (Jun 27 2026) 12 Months Ending (Mar 28 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 27 2025)
Cumulative Revenue 12 Months Ending $ 585.32
Y / Y Revenue Growth (TTM) 3.85 %
Year on Year Revenue Growth Overall Ranking # 2059
Seqeuential Revenue Change (TTM) 0.72 %
Seq. Revenue Growth (TTM) Overall Ranking # 2647


Cumulative Revenue growth Comment
Although Bioventus Inc 's Annual Revenue growth year on year were below company's average 11.38% , Revenue announced in the Sep 26 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 3.85% year on year, from 3.05% in Jun 27 2026.

In the Healthcare sector 311 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1062 to 2059.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 140
Healthcare Sector # 312
Overall # 2059

Revenue TTM Y/Y Growth Statistics
High Average Low
43.64 %
 11.38 %
-2.83 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 140
Sector # 382
S&P 500 # 2647
Cumulative Revenue growth Comment
Although Bioventus Inc 's Annual Revenue growth year on year were below company's average 11.38% , Revenue announced in the Sep 26 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 3.85% year on year, from 3.05% in Jun 27 2026.

In the Healthcare sector 311 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1062 to 2059.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 140
Healthcare Sector # 312
Overall # 2059

Revenue TTM Y/Y Growth Statistics
High Average Low
43.64 %
11.38 %
-2.83 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 140
Sector # 382
S&P 500 # 2647




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
BVS's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Sep 26 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 26 2026
Universal Health Services Inc 5.30%$ 5.297 millions
Acadia Healthcare Company Inc 5.14%$ 5.136 millions
Lumexa Imaging Holdings Inc 5.03%$ 5.032 millions
Bio techne Corp4.75%$ 4.753 millions
Merck and Co Inc 4.68%$ 4.683 millions
Davita Inc 4.62%$ 4.617 millions
Sotera Health Company4.61%$ 4.613 millions
Avantor Inc 4.59%$ 4.588 millions
Icu Medical Inc4.39%$ 4.388 millions
Illumina Inc 4.15%$ 4.151 millions
Agenus Inc4.14%$ 4.144 millions
United Therapeutics Corporation4.13%$ 4.128 millions
Option Care Health Inc 4.09%$ 4.086 millions
Henry Schein Inc 3.95%$ 3.953 millions
Grail Inc 3.71%$ 3.705 millions
Docgo Inc 3.70%$ 3.702 millions
Hca Healthcare Inc 3.59%$ 3.591 millions
Collegium Pharmaceutical Inc 3.43%$ 3.427 millions
Healthcare Services Group Inc 3.29%$ 3.288 millions
Cytek Biosciences Inc 3.26%$ 3.255 millions
Zimmer Biomet Holdings Inc 3.07%$ 3.073 millions
Ardent Health Inc 3.05%$ 3.051 millions
Bioventus Inc 3.05%$ 3.048 millions
Infusystem Holdings Inc3.02%$ 3.017 millions
Integra Lifesciences Holdings Corp2.27%$ 2.268 millions
Align Technology inc 1.97%$ 1.966 millions
Pediatrix Medical Group Inc 1.72%$ 1.724 millions
Lantheus Holdings Inc 1.71%$ 1.708 millions
10x Genomics Inc 1.59%$ 1.591 millions
Bruker Corporation1.58%$ 1.581 millions


About Bioventus Inc Revenue Growth Rates (BVS), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Bioventus Inc (CIK 1665988).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001665988-26-000052
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Bioventus Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.